Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0227

Advisory board · Dr. Ximena Fischer

20 Apr 2026 · Phone · Dr. Ximena Fischer, LMU Klinikum München · MSL Rachel Adeyemi · Aurelin

ReviewedVeeva CRMENG-0227—

Capture insight from this engagement

Location: LMU Klinikum München
Therapeutic area: Immunology
Country: Germany
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Aurelin (aurelinate)

Topics discussed

JAK1/TYK2 selectivity
Adolescent population

Scientific content used

JAK selectivity review
ARL Phase IIb summary

Questions raised

When will adolescent data be available?

Notes

Advisory board with dermatologist at LMU Klinikum München. Discussed jak1/tyk2 selectivity, adolescent population.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Share MI standard response

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 5
Depth of exchange: 4
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0227

Audit history (0)

All create, update and approval events for this record

No audit events in sample data